Clinical trial
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization…
NCT00251459 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00251459 |
|---|---|
| Title | A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
| Official title | A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Choroidal Neovascularization, Age-related Macular Degeneration |
| Intervention type | Drug |
| Interventions | rhuFab V2 (ranibizumab) |
| Enrollment | 5,000 |
| Start date | Nov 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Nov 10, 2005 |
| Last update posted | Mar 10, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: